

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

OBITUARY

MOURNING THE PASSING OF DR. NING ZHAO

It is with deep sadness that the board of directors (the “**Board**”) of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) share the news that Dr. Ning Zhao (“**Dr. Zhao**”), the co-founder, one of the actual controllers, executive director and senior vice president of the Company, has passed away on May 16, 2023.

Dr. Zhao was an extraordinary scientist, leader and philanthropist with an unwavering commitment to improving human health. She obtained her bachelor’s degree in chemistry from Peking University, doctoral degree in organic chemistry from Columbia University, and then began her remarkable career with top organizations, advancing through the ranks of research and management. As one of our co-founders, Dr. Zhao played an instrumental role in shaping our Company into what it is today. She built our integrated bioanalytical capabilities with global regulatory standards — a cornerstone of our testing platform and CRDMO/CTDMO model today. She also spearheaded the Company’s talent development strategies and HR transformations that have become award-winning industry best practices.

During her long battle against cancer, her strong sense of purpose led to her tireless global philanthropic efforts to support cancer research and foster future leaders so new treatments and cures will benefit patients around the world.

Dr. Zhao will be deeply missed. Her vision and spirit will live on through all of us, and guide our Company forward towards a future where every drug can be made, and every disease can be treated.

Following the passing away of Dr. Zhao, the current number of directors of the company has been reduced from 13 to 12, which is not lower than the minimum number of board members required by the Company Law of the People's Republic of China, but lower than that required by the articles of association of the Company. The Company will endeavor to seek suitable candidates and elect a new director as soon as practicable in order to comply with the abovementioned requirement of the articles of association of the Company.

Currently, the Company's production and operation activities remain stable and are being conducted in a normal manner. The Board, the supervisory committee and members of the senior management of the Company will continue to perform their duties in a normal manner. All employees of the Company will continue to act diligently and conscientiously, and devote themselves to the long-term development of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, May 17, 2023

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Dr. Minzhang Chen and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Dr. Hetong Lou, Mr. Xiaotong Zhang and Mr. Dai Feng as independent non-executive Directors.

* *For identification purposes only*